Ixekizumab is a monoclonal antibody biologic marketed as Taltz for multiple inflammatory conditions including plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and pediatric plaque psoriasis in eligible patients. It is administered by subcutaneous injection with indication-specific loading and maintenance schedules. U.S. approval began in 2016.
Lilly said a Phase IIIb trial of ixekizumab plus tirzepatide in psoriasis and obesity or overweight beat ixekizumab alone on complete skin clearance plus at least 10% weight loss at 36 weeks.
Eli Lilly reported positive phase 3b Together-PsO results for Taltz plus Zepbound in adults with plaque psoriasis and obesity or overweight. Separate meeting updates highlighted new oral plaque psoriasis therapies with biologic-like efficacy.
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
The FDA has approved icotrokinra, the first oral IL-23 therapy for moderate-to-severe plaque psoriasis. Meanwhile, real-world research shows IL-23 inhibitors produce site-specific responses in high-impact areas like scalp and nails, and combination therapy with ixekizumab and tirzepatide shows superior results for psoriasis patients with obesity.
Phase 3b TOGETHER-PsO trial shows concomitant use of ixekizumab and tirzepatide delivered superior skin clearance and weight loss versus monotherapy in adults with moderate-to-severe plaque psoriasis and obesity or overweight.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07443956 |
Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis |
RECRUITING | NA |
| NCT06588296 |
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight |
COMPLETED | PHASE3 |
| NCT04589325 |
Ixekizumab Diabetes Intervention Trial (I-DIT) |
ACTIVE_NOT_RECRUITING | PHASE2 |
